Fondaparinux : mise au point et perspectives

Bounameaux, 2002, Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention, Lancet, 18, 1710, 10.1016/S0140-6736(02)08660-9 Girardel, 2006, Les nouveaux antithrombotiques : une thérapeutique en mutation, des perspectives d’avenir, Réanimation, 15, 117, 10.1016/j.reaurg.2005.12.024 Samama, 2003, Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux), Thrombosis Res, 109, 1, 10.1016/S0049-3848(03)00030-6 Turpie, 2003, Fondaparinux and prevention of venous thromboembolism after orthopedic surgery, Lancet, 8, 1582, 10.1016/S0140-6736(03)14753-8 Bauer, 2001, Fondaparinux compared with enoxaparine for the prevention of venous thromboembolism after elective major knee surgery, N Engl J Med, 345, 1305, 10.1056/NEJMoa011099 Lassen, 2002, Postoperative fondaparinux versus preoperative enoxaparine for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison, Lancet, 18, 1715, 10.1016/S0140-6736(02)08652-X Eriksson, 2001, Fondaparinux compared with enoxaparine for the prevention of venous thromboembolism after hip fracture surgery, N Engl J Med, 345, 1298, 10.1056/NEJMoa011100 Agnelli, 2005, Randomised clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery, Br J Surg, 92, 1212, 10.1002/bjs.5154 Cohen, 2006, Br Med J, 332, 325, 10.1136/bmj.38733.466748.7C Eriksson, 2003, Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study, Arch Intern Med, 163, 1337, 10.1001/archinte.163.11.1337 Turpie, 2002, Fondaparinux versus enoxaparine for the prevention of venous thrombo embolism in major orthopedic surgery: a meta analysis of 4 randomised double –blind studies, Arch Intern Med, 162, 1833, 10.1001/archinte.162.16.1833 2000, Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti –factor Xa activity. A phase II evaluation, Circulation, 102, 2726, 10.1161/01.CIR.102.22.2726 2003, Subcutaneous Fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism, N Engl J Med, 349, 1695, 10.1056/NEJMoa035451 Büller, 2004, Lensing AWA, for the Matisse investigators Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomised trial, Ann Intern Med, 140, 867, 10.7326/0003-4819-140-11-200406010-00007 Simoons, 2004, A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study, J Am Coll Cardiol, 43, 2183, 10.1016/j.jacc.2004.02.051 Michelangelo Oasis 5 steering committee, 2005, Design and rationale MICHELANGELO organization to assess strategies in acute ischemic syndrome (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor X a inhibitor, in patients with non ST segment elevation acute coronary syndrome, Am Heart J, 150, e1, 10.1016/j.ahj.2005.08.014 Coussement, 2001, A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study, Eur Heart J, 22, 1716, 10.1053/euhj.2001.2777 Gruel, 2004, Heparin-induced thrombocytopenia: pathogenesis, diagnosis, treatment, Rev Med Int, 25, 35, 10.1016/S0248-8663(03)00109-7 Warkentin, 2005, New approaches to the diagnosis of heparin-induced thrombocytopenia, Chest, 127, 35S, 10.1378/chest.127.2_suppl.35S Elalamy, 1995, Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia, Thromb Haemost, 74, 1384, 10.1055/s-0038-1649949 Warkentin, 2004, Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 311S, 10.1378/chest.126.3_suppl.311S Société française d’anesthésie reanimation, 2003, Conférence d’experts. Thrombopénie induite par l’héparine, Ann Fr Anesth Reanim, 22, 150 Savi, 2005, Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin, Blood, 105, 139, 10.1182/blood-2004-05-2010 Amiral, 1997, Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia, Blood Coagul Fibrinolysis, 8, 114, 10.1097/00001721-199703000-00005 Spinler, 2006, New concepts in Heparin-induced thrombocytopenia: diagnosis and management, J Thromb Thrombolysis, 21, 17, 10.1007/s11239-006-5571-z Papadopoulos, 2007, Fondaparinux as a treatment option for heparin-induced thrombocytopenia, Pharmacotherapy, 27, 921, 10.1592/phco.27.6.921 Kuo, 2005, Fondaparinux: a potential new therapy for HIT, Hematology, 10, 271, 10.1080/10245330500093492 Efird, 2006, Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia, Ann Pharmacother, 40, 1383, 10.1345/aph.1G738 Warkentin, 2005, Anti-platelet factor4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin, Blood, 106, 3791, 10.1182/blood-2005-05-1938 Warkentin, 2007, Heparin-induced thrombocytopenia associated with fondaparinux, N Engl J Med, 356, 2654 Hirsh, 2005, New Anticoagulants, Blood., 105, 453, 10.1182/blood-2003-12-4195 Smogorzewska A, Brandt JT, Chandler WL, Cunningham MT, Hayes TE, Olson JD, Kottke-Marchant K, Van Cott EM. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Ludwig, 2006, Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing, Laryngorhinootologie, 85, 50 Gosselin, 2004, Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing, Arch Pathol Lab Med, 128, 1142, 10.5858/2004-128-1142-EOPFAD Gosselin, 2003, Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing, Blood Coagul Fibrinolysis, 14, 557 Eriksson, 2007, A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary replacement hip surgery, J Thromb Haemost, 5, 1660, 10.1111/j.1538-7836.2007.02644.x Agnelli, 2007, A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement, J Thromb Haemost, 5, 746, 10.1111/j.1538-7836.2007.02436.x Agnelli, 2007, Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study, Circulation, 116, 180, 10.1161/CIRCULATIONAHA.106.668020 PERSIST investigators, 2004, A novel long-acting synthetic factor Xa inhibitor (SanOrg 34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation, J Thromb Haemost, 2, 47, 10.1111/j.1538-7836.2003.00516.x